

Relationships between the Nicotine Metabolite Ratio and a Panel of Exposure and Effect Biomarkers: Findings from Two Studies of U.S. Commercial Cigarette Smokers



Dana M. Carroll^{1,2}, Sharon E. Murphy¹, Neal L. Benowitz³, Andrew A. Strasser⁴, Michael Kotlyar^{1,5}, Stephen S. Hecht¹, Steve G. Carmella¹, Francis J. McClernon⁶, Lauren R. Pacek⁶, Sarah S. Dermody⁷, Ryan G. Vandrey⁸, Eric C. Donny⁹, and Dorothy K. Hatsukami¹

ABSTRACT

Background: We examined the nicotine metabolite ratio's (NMR) relationship with smoking intensity, nicotine dependence, and a broad array of biomarkers of exposure and biological effect in commercial cigarette smokers.

Methods: Secondary analysis was conducted on two cross-sectional samples of adult, daily smokers from Wave 1 (2013–2014) of the Population Assessment of Tobacco Use and Health (PATH) Study and baseline data from a 2014–2017 randomized clinical trial. Data were restricted to participants of non-Hispanic, white race. The lowest quartile of NMR (<0.26) in the nationally representative PATH Study was used to distinguish slow from normal/fast nicotine metabolizers. NMR was modeled continuously in secondary analysis.

Results: Compared with slow metabolizers, normal/fast metabolizers had greater cigarettes per day and higher levels of total nicotine equivalents, tobacco-specific nitrosamines, volatile organic

compounds, and polycyclic aromatic hydrocarbons. A novel finding was higher levels of inflammatory biomarkers among normal/fast metabolizers versus slow metabolizers. With NMR modeled as a continuous measure, the associations between NMR and biomarkers of inflammation were not significant.

Conclusions: The results are suggestive that normal/fast nicotine metabolizers may be at increased risk for tobacco-related disease due to being heavier smokers, having higher exposure to numerous toxicants and carcinogens, and having higher levels of inflammation when compared with slow metabolizers.

Impact: This is the first documentation that NMR is not only associated with smoking exposure but also biomarkers of biological effects that are integral in the development of tobacco-related disease. Results provide support for NMR as a biomarker for understanding a smoker's exposure and potential risk for tobacco-related disease.

Introduction

Nicotine, the main addictive substance in cigarettes (1), is metabolized primarily to cotinine (COT) by the cytochrome P450 2A6 (CYP2A6) enzyme (2, 3). CYP2A6 also metabolizes COT, the predominant metabolite of nicotine, to 3'-hydroxycotinine (3-HCOT; ref. 2). For this reason, the nicotine metabolite ratio (NMR) of 3-HCOT/COT is a phenotypic biomarker for CYP2A6 enzyme activity

where lower ratios are reflective of low/null activity CYP2A6 variants and are indicative of a slower nicotine metabolism rate (4–6). Considering that an estimated 20% of the variability in NMR is due to environmental and hormonal factors, NMR provides a more complete picture of nicotine clearance than CYP2A6 genotype (2, 7).

Previous studies have shown that the NMR is associated with heaviness of smoking and exposure to some tobacco biomarkers (5, 8, 9). A systematic review found that normal/fast nicotine metabolizers smoke more cigarettes per day (CPD) than slow metabolizers (8). In line with these data are a topography study that observed fast metabolizers (quartile 4 of NMR) smoke each cigarette more intensely (i.e., larger puff volume) than slower metabolizers (quartile 1 of NMR; ref. 9). In a large study of smokers representing multiple races with varying levels of lung cancer (i.e., whites, African Americans, Japanese Americans), the association of NMR (modeled continuously) and CYP2A6 variants with heaviness of smoking, measured by the sum of urinary nicotine and its metabolites (i.e., total nicotine equivalents; TNE), was examined (5). The authors found a strong association between NMR and CYP2A6 variants with TNE (5). Their results provide evidence for decreased nicotine uptake and consequently decreased toxicant exposure from tobacco and tobacco smoke as the mechanism by which low or null activity CYP2A6 variants and a reduced NMR lead to the lower cancer risk in Japanese American smokers (5). Complementing these results are studies demonstrating metabolites of the lung carcinogen NNK, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol and its glucuronides (total NNAL), were lower among smokers with low/null activity CYP2A6 variants and considered slow metabolizers based on NMR (5, 9, 10). The evidence from these studies suggest that the higher levels of

¹Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota. ²Division of Environmental Health Sciences, School of Public Health, University of Minnesota, Minneapolis, Minnesota. ³Clinical Pharmacology Program, Division of Cardiology, Department of Medicine, University of California, San Francisco, California. ⁴Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania. ⁵Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota. ⁶Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, North Carolina. ⁷School of Psychological Science, Oregon State University, Corvallis, Oregon. ⁸Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, Maryland. ⁹Department of Physiology and Pharmacology, Wake Forest School of Medicine, Winston-Salem, North Carolina.

Note: Supplementary data for this article are available at Cancer Epidemiology, Biomarkers & Prevention Online (<http://cebp.aacrjournals.org/>).

Corresponding Author: Dana M. Carroll, Division of Environmental Health Sciences, School of Public Health, University of Minnesota, 717 Delaware Street SE, Minneapolis, MN 55414. Phone: 612-624-4913; E-mail: dcarroll@umn.edu

Cancer Epidemiol Biomarkers Prev 2020;29:871–9

doi: 10.1158/1055-9965.EPI-19-0644

©2020 American Association for Cancer Research.

Carroll et al.

exposure to nicotine and the harmful constituents found in tobacco and tobacco smoke may result from normal/fast metabolizers smoking a greater number of CPD and/or smoking each cigarette more intensely than slow metabolizers.

Further study of the relationships between NMR and exposure levels to harmful constituents found in tobacco smoke, such as volatile organic compounds (VOC) and polycyclic aromatic hydrocarbons (PAH), and biomarkers of biological effect such as inflammation and oxidative stress would provide a more comprehensive picture of a smoker's risk for tobacco-related disease based on NMR than have prior studies. The purpose of this study was to examine NMR's relation with nicotine dependence, smoking intensity, and an array of tobacco biomarkers of exposure and biological effect. The datasets analyzed, the U.S. Population Assessment of Tobacco Use and Health (PATH) study and baseline data from a randomized clinical trial (RCT) of daily cigarette smokers, were both selected for analysis because their combined use resulted in a greater array of biomarkers for study. The central hypothesis was that NMR would be associated with greater smoking intensity and nicotine dependence, and higher levels of biomarkers of tobacco-specific nitrosamines (TSNA), VOCs, PAHs, inflammation, and oxidative stress. If confirmed, findings will provide strong evidence for the utility of NMR in understanding exposure and potential health risks from smoking.

Methods

Data sources

The Population Assessment of Tobacco Use and Health (PATH) study is a nationally representative, longitudinal cohort study of adult and youth in the United States, aged 12 years and older (11). Wave 1 was conducted from September 2013 to December 2014 (11). Field interviewers visited the respondent's home to conduct the interview using audio computer-assisted self-interviews to collect self-report information such as tobacco use behavior (11). From adults who consented to provide them, urine and blood samples were collected. A urine sample was collected immediately following the completion of the interview, while blood was collected at a separate visit by a phlebotomist who visited the respondent's home after the interview at a time scheduled by the field interviewer (11). Address-based, area-probability sampling was used for recruitment (11). Data is weighted so that estimates are representative of the civilian, noninstitutionalized U.S. population. Additional information on the design and methods of the PATH study are available elsewhere (11).

For the current analysis, Wave 1 PATH adult data ($n = 32,320$) was restricted to daily established cigarette smokers ($n = 9,021$; i.e., defined as persons who have ever smoked a cigarette, have smoked more than 100 cigarettes in their lifetime, and currently smoke every day) who were included in the urine data collection ($n = 4,862$) and at the time of the urine sample reported having smoked sometime that day ($n = 4,575$). Data was further restricted to participants who were included in the blood data ($n = 3,012$). Next, data was restricted to those with a urinary COT level of $>1,000$ ng/mL to confirm regular smoking status ($n = 2,734$) and to facilitate comparison of the PATH study data to baseline data from the RCT (described below). Data were further restricted to participants reporting non-Hispanic white race/ethnicity ($n = 2,153$) to avoid racial differences in nicotine metabolism pathways that may affect the relationship between NMR and nicotine clearance (2, 12). Participants who were also established users of other tobacco (i.e., persons who self-reported using fairly regularly and

using every day or some day use) were excluded ($n = 1,436$) so that biomarker levels were not confounded. Experimental users of other tobacco products (i.e., persons who self-reported having never used fairly regularly) were included. Finally, participants considered outliers for cigarettes per day, reporting more than 80 CPD, or missing data on serum NMR were excluded. This resulted in a final unweighted analysis set of 1,422 participants.

Secondary data analysis was also conducted on baseline data from a RCT examining the effects of an immediate versus step down approach to reducing nicotine content levels in cigarettes. The RCT was conducted from 2014 to 2017 at 10 U.S. sites (clinicaltrials.gov Identifier: NCT02139930). To be eligible, individuals at the time of screening were of legal age to purchase tobacco; breath alcohol level $<0.02\%$; smoked ≥ 5 cigarettes per day (CPD); had an expired carbon monoxide level of >8 ppm or if ≤ 8 ppm than a urinary COT level of $>1,000$ ng/mL. Exclusion criteria were breastfeeding, pregnant, or planning to become pregnant; intentions to quit smoking in the next 30 days; used roll-your own cigarettes exclusively or tobacco products other than cigarettes for >9 days of the past 30 days; had previously used reduced nicotine content study cigarettes; unstable or serious psychiatric or medical conditions; and positive urine toxicology for illicit drug use (excluding THC). Refer to Hatsukami and colleagues 2018 for additional details on the study design and participants (13). For this analysis, baseline data ($n = 1,250$) were restricted to smokers reporting non-Hispanic white race/ethnicity ($n = 758$) who provided a blood and urine sample at baseline ($n = 739$).

NMR

NMR was measured as the molar ratio of free (unconjugated) 3-hydroxycotinine to free cotinine (3HCOT/COT) in serum in both the PATH study and the RCT (13, 14).

Smoking intensity

CPD was assessed in the PATH and the RCT by the following question: On average, about how many cigarettes do you now smoke each day? In the RCT only, all participants provided a measurement of exhaled breath carbon monoxide (CO). In both the PATH study and the RCT, urinary total nicotine equivalents (TNE) overall and divided by CPD (TNE/CPD) were examined to estimate nicotine dose and nicotine dose per cigarette smoked, respectively. See below for further details on TNE.

Nicotine dependence

Heaviness of Smoking Index (HSI; ref. 15) and versions of the Brief Wisconsin Inventory of Smoking Dependence Motives (WISDM; ref. 16) were available in both the PATH and the RCT datasets and examined in this analysis. The HSI uses a 6-point scale calculated from the average number of CPD (1–10, 11–20, 21–30, 30+) and time to first cigarette upon waking (<5 , 5–30, 31–60, >60 minutes; ref. 15). In PATH, 8 items of the Brief WISDM primary dependence motives subscale (PDM8), comprising items from each of the four domains encompassed by the PDM (i.e., automaticity, craving, loss of control, and tolerance) were available and were examined. Participants were asked to rate their level of agreement for each item using a Likert scale from 1 (not true of me at all) to 5 (extremely true of me; ref. 17). For each participant, PDM8 was calculated as the mean of the 8 items. In the RCT, all 16 items of the WISDM PDM (PDM16) were available and were examined. Participants were asked to rate their level of agreement for each item using a Likert scale from 1 (not true of me at all) to 7 (extremely true of me). For each participant, PDM16 was calculated as the mean of the 16 items.

Biomarkers of exposure and biological effect

Table 1 provides a summary of the biomarkers measured and their data source. In PATH, assays of TNE (molar sum of total nicotine, total COT, total 3-HCOT, total cotinine *N*-oxide, total nicotine *N*-oxide, total norcotinine, and total nornicotine; where "total" refers to the sum of unconjugated and glucuronide-conjugated compounds) and the following biomarkers of toxicant exposure have been previously described: (14) total NNAL, total NNN, 3-HPMA, 2-HPMA, SPMA, HMPMA, CEMA, AAMA, MHB3, PGA, HEMA, MADA, 1-HOP, 2-FLU, and 1-NAP. In PATH, the following biomarkers of biological effect have also been described previously: (14) 8-*iso*-PGF_{2α}, ICAM-1, IL6, and hsCRP. Assays of urinary biomarkers of exposure in the RCT were carried out in the Analytical Biochemistry Shared Resource of the Masonic Cancer Center, University of Minnesota as previously described for TNE (molar sum of total nicotine, total COT, and total 3-HCOT; ref. 18), total NNAL (19), 3-HPMA (20), 2-HPMA (21), SPMA (22), HMPMA (20), CEMA (23), and PheT (19). The Masonic Cancer Center also carried out assays of the following biomarkers of biological effect in the RCT: 8-*iso*-PGF_{2α} (24) and PGEM (25). Routine assays of the blood biomarkers of biological effect, hsCRP and WBC, in the RCT were conducted by the Advanced Research and Diagnostic Laboratory at the University of Minnesota and Health East Medical Laboratories.

Statistical analysis

Prior studies have observed the distribution of NMR to be nonlinear (26–31). Furthermore, these studies have observed NMR's validity for predicting nicotine exposure and smoking cessation to be greatest when the lowest quartile of NMR is compared with the highest three quartiles (26–31). On the basis of these studies, the lowest quartile of NMR in the U.S. representative PATH study was used to distinguish slow from normal/fast nicotine metabolizers in this study. The same cutoff was applied to baseline data from the RCT to distinguish slow from normal/fast metabolizers. In a secondary analysis, NMR (log-transformed) was modeled as a continuous variable in both datasets.

Self-report measures including demographics, nicotine dependence, and smoking history were summarized across NMR group (slow vs. normal/fast metabolizers) by means or proportions and 95% confidence intervals (CI). Urinary biomarker values were normalized for creatinine (biomarker/creatinine) to account for differences in urinary output across participants. All biomarkers had skewed distributions and were transformed using the natural logarithm to approximate normality and summarized using geometric means (GM) and 95% CI.

Linear regression modeling was used to assess statistically significant differences, at $P < 0.05$, between slow versus normal/fast metabolizers in terms of smoking intensity, nicotine dependence, and biomarkers of exposure and biological effect. Models were run with

Table 1. Biomarkers of tobacco exposure and biological effect.

Constituent	Biomarkers of exposure	Sample	Data source(s)
Nicotine	Total nicotine equivalents (TNE) ^a	Urine	PATH and RCT
Tobacco specific nitrosamines			
4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone ^b	4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol and its glucuronides (total NNAL)	Urine	PATH and RCT
<i>N</i> '-Nitrosornicotine ^b	<i>N</i> '-nitrosornicotine and its glucuronides (total NNN)	Urine	PATH
Volatile organic compounds			
Acrolein ^b	<i>N</i> -Acetyl-S-(3-hydroxypropyl)-L-cysteine (3-HPMA)	Urine	PATH and RCT
Propylene oxide ^b	<i>N</i> -Acetyl-S-(2-hydroxypropyl)-L-cysteine (2-HPMA)	Urine	PATH and RCT
Benzene ^b	<i>N</i> -Acetyl-S-(phenyl)-L-cysteine (SPMA)	Urine	PATH and RCT
Crotonaldehyde ^b	<i>N</i> -Acetyl-S-(3-hydroxypropyl-1-methyl)-L-cysteine (HMPMA)	Urine	PATH and RCT
Acrylonitrile ^b	<i>N</i> -Acetyl-S-(2-cyanoethyl)-L-cysteine (CEMA)	Urine	PATH and RCT
Acrylamide ^b	<i>N</i> -Acetyl-S-(2-carbamoyl-ethyl)-L-cysteine (AAMA)	Urine	PATH
1,3-Butadiene ^b	<i>N</i> -Acetyl-S-(4-hydroxy-2-butenyl)-L-cysteine (MHB3)	Urine	PATH
Ethylbenzene ^b /Styrene ^b	Phenylglyoxylic acid (PGA)	Urine	PATH
Acrylonitrile ^b ; Vinyl chloride ^b ; Ethylene oxide ^b	<i>N</i> -Acetyl-S-(2-hydroxyethyl)-L-cysteine (HEMA)	Urine	PATH
Styrene ^b	Mandelic acid (MADA)	Urine	PATH
Polycyclic aromatic hydrocarbons			
Pyrene	1-Hydroxypyrene (1-HOP)	Urine	PATH
Fluorene	2-Hydroxyfluorene (2-FLU)	Urine	PATH
Naphthalene	1-Hydroxynaphthalene (1-NAP)	Urine	PATH
Phenanthrene	Phenanthrene tetraol (PheT)	Urine	RCT
Indication			
Oxidative stress	8- <i>iso</i> -prostaglandin F _{2α} (8- <i>iso</i> -PGF _{2α})	Urine	PATH and RCT
Inflammation	Prostaglandin E metabolite (PGEM)	Urine	RCT
Inflammation	Soluble Intercellular Adhesion Molecular (ICAM-1)	Serum	PATH
Inflammation	IL6	Serum	PATH
Inflammation	High-sensitivity C-reactive protein (hsCRP)	Serum	PATH and RCT
Inflammation	White blood cells (WBC)	Blood	RCT

^aIn the RCT, TNE is the molar sum of total nicotine, total cotinine, and total 3'-hydroxycotinine, where "total" refers to the unconjugated and glucuronide-conjugated forms. In PATH, TNE is the molar sum of total nicotine, total cotinine, total 3'-hydroxycotinine, total cotinine *N*-oxide, total nicotine *N*-oxide, total norcotinine, and total nornicotine.

^bIncluded on the Food and Drug Administration list of harmful or potentially harmful constituents in tobacco or tobacco smoke (24).

Carroll et al.

NMR group as an independent variable and adjusted for the following covariates that have been shown to be associated with NMR and outcomes of interest: sex, age, duration of regular smoking, body mass index (BMI), and menthol status (2, 7, 32, 33). Analyses were repeated for NMR as a continuous variable. All analyses using PATH data were performed using survey procedures and weights that adjust for the complex sampling design. Blood biomarker weights were used in all analyses of the PATH data, because a smaller subset of respondents provided a blood versus a urine sample (14). PATH data variances were estimated by the balanced repeated replication method (34) with Fay adjustment set to 0.3 to increase estimate stability (35). All analyses were performed in SAS 9.4.

Results

PATH data presented in the tables and figures were weighted to reflect the U.S. adult population at the time of the Wave 1 (2013–2014) sample. In PATH, the first quartile, median, and third quartile values of NMR were 0.262 (95% CI: 0.246–0.277), 0.379 (95% CI: 0.361–0.396), and 0.506 (95% CI: 0.480–0.532), respectively. Using the first quartile value of NMR (0.262) as the cutoff, the unweighted sample sizes for slow and normal/fast nicotine metabolizers were $n = 343$ and $n = 1,078$, respectively. In the RCT, the first quartile, median, and third quartile values of NMR were 0.29, 0.40, and 0.55, respectively. Using the first quartile of NMR (0.262) in the PATH study as the cutoff, the sample sizes for slow and normal/fast nicotine metabolizers were $n = 148$ and $n = 591$, respectively, in the RCT.

Characteristics of the participants by NMR group are displayed in **Table 2**. A greater proportion of normal/fast nicotine metabolizers

versus slow nicotine metabolizers were female, which is consistent with prior studies that have demonstrated sex hormones influence nicotine metabolism (32). In the PATH study, normal/fast metabolizers had an older average age and a greater duration of regular smoking than slow metabolizers. In the RCT, normal/fast metabolizers had a lower average BMI than slow metabolizers.

The mean value of the HSI, after adjustment for age, gender, BMI, duration of smoking, and menthol use, was greater among normal/fast metabolizers than slow metabolizers (3.28 vs. 2.95; $P = 0.0178$) in the PATH study. Further examination of the two items comprising the HSI demonstrated that the significance observed in the PATH study was driven by number of CPD ($P = 0.0027$) and not time to first cigarette smoked upon waking ($P = 0.8985$). In the RCT, there was no difference in the HSI (3.35 vs. 3.34; $P = 0.9447$). The mean value of the WISDM PDM8 in the PATH study and the mean value of the PDM16 in the RCT did not differ by NMR.

Unadjusted results comparing frequency and intensity of smoking and biomarkers of exposure and effect across NMR group are displayed in Supplementary Tables S1 and S2. Results of the analyses examining smoking intensity measures by NMR group adjusted for covariates are displayed in **Fig. 1**. In the PATH Study, normal/fast nicotine metabolizers had greater CPD than slow metabolizers (18.07 vs. 15.69; $P = 0.0008$). In the RCT, normal/fast metabolizers and slow metabolizers did not differ in average CPD (19.34 vs. 18.42; $P = 0.2597$). In both datasets, normal/fast nicotine metabolizers versus slow metabolizers had higher average levels of TNE (PATH: 84.61 vs. 64.53 nmol/mg; $P < 0.0001$; RCT: 68.33 vs. 57.55 nmol/mg; $P = 0.0004$) and TNE per cigarette smoked (PATH: 5.33 vs. 4.67 nmol/mg; $P < 0.0001$; RCT: 3.92 vs. 3.48 nmol/mg; 0.0139).

Table 2. Means, geometric means (GM), or proportions (%) and 95% confidence intervals of covariates by NMR and data source.

	Slow metabolizers	Normal/fast metabolizers	P
PATH Wave 1			
	<i>N</i> = 4,642,172	<i>N</i> = 13,941,182	
Age (years), mean	40.23 (38.10–42.37)	45.47 (43.97–46.97)	0.0002
Female sex, %	40.79 (32.99–49.09)	59.51 (55.20–63.68)	<0.0001
Body mass index, mean	27.82 (26.94–28.70)	27.14 (26.54–27.75)	0.1864
Years smoking, mean	21.92 (19.51–24.34)	26.35 (25.16–27.55)	0.0013
Smokes menthol cigarettes, %	27.13 (21.99–32.97)	30.10 (24.54–36.32)	0.4344
Urinary creatinine, GM	1.11 (1.00–1.22)	0.88 (0.82–0.94)	0.0004
HSI, mean	3.02 (2.80–3.23)	3.27 (3.11–3.44)	0.0510
HSI ^a , mean	2.95 (2.73–3.17)	3.28 (3.07–3.48)	0.0178
WISDM PDM8, mean	3.30 (3.16–3.43)	3.44 (3.35–3.54)	0.0778
WISDM PDM8 ^a , mean	3.35 (3.22–3.48)	3.43 (3.33–3.53)	0.2884
Baseline data from RCT			
	<i>N</i> = 148	<i>N</i> = 591	
Age (years), mean	43.41 (41.27–45.54)	45.36 (44.17–46.54)	0.1392
Female sex, %	33.78 (26.15–41.42)	47.88 (43.85–51.92)	0.0020
Body mass index, mean	29.71 (28.69–30.72)	28.50 (27.97–29.01)	0.0376
Years smoking, mean	26.20 (24.06–28.34)	28.23 (27.04–29.41)	0.1245
Smokes menthol cigarettes, %	30.41 (22.98–37.84)	23.35 (19.93–26.77)	0.0754
Urinary creatinine, GM	1.00 (0.90–1.12)	0.95 (0.90–1.01)	0.4085
Expired CO, mean	20.08 (18.64–21.51)	20.93 (20.12–21.73)	0.3431
HSI, mean	3.42 (3.19–3.65)	3.41 (3.29–3.52)	0.9315
HSI ^a , mean	3.34 (3.10–3.57)	3.35 (3.21–3.48)	0.9447
WISDM PDM16, mean	4.26 (4.04–4.48)	4.23 (4.12–4.35)	0.8415
WISDM PDM16 ^a , mean	4.27 (4.04–4.50)	4.22 (4.08–4.35)	0.6739

Note: PATH data are weighted; parentheses include 95% confidence intervals; bold values indicate statistical significance at $P < 0.05$.

Abbreviation: GM, geometric mean.

^aEstimates adjusted for age, sex, body mass index, duration regular smoking, and menthol use.

NMR and Exposure and Effect Biomarkers




Figure 1.

Geometric means and 95% confidence intervals of heaviness of smoking measures by NMR strata. All estimates are adjusted for age, sex, body mass index, duration regular smoking, and menthol use. * Indicates a statistically significant difference ($P < 0.05$) in normal/fast nicotine metabolizers when compared with slow metabolizers.

Results of the adjusted analyses examining biomarkers of exposure across slow and normal/fast nicotine metabolizers are displayed in **Fig. 2**. In the PATH Study, normal/fast nicotine metabolizers versus slow nicotine metabolizers had higher average

values of total NNAL (1.85 vs. 1.35 pmol/mg; $P < 0.0001$), 3-HPMA (7.64 vs. 6.14 nmol/mg; $P < 0.0001$), 2-HPMA (0.40 vs. 0.34 nmol/mg; $P = 0.0049$), HMPMA (15.25 vs. 12.06 nmol/mg; $P < 0.0001$), CEMA (0.99 vs. 0.73 nmol/mg; $P < 0.0001$), AAMA





Figure 2.

Geometric means and 95% confidence intervals of biomarkers of tobacco-specific nitrosamines, volatile organic compounds, and polycyclic aromatic hydrocarbons by NMR strata. All estimates are adjusted for age, sex, body mass index, duration regular smoking, and menthol use. * Indicates a statistically significant difference ($P < 0.05$) in normal/fast nicotine metabolizers when compared with slow metabolizers.

Carroll et al.

**Figure 3.**

Geometric means and 95% confidence intervals of biomarkers of oxidative stress and inflammation by NMR strata. All estimates are adjusted for age, sex, body mass index, duration regular smoking, and menthol use. * Indicates a statistically significant difference ($P < 0.05$) in normal/fast nicotine metabolizers when compared with slow metabolizers.

(0.74 vs. 0.60 nmol/mg; $P < 0.0001$), MHB3 (0.18 vs. 0.15 nmol/mg; $P = 0.00013$), PGA (3.01 vs. 2.61 nmol/mg; $P = 0.0010$), MADA (2.13 vs. 1.86 nmol/mg; $P = 0.0020$), 1-HOP (1.77 vs. 1.45 pmol/mg; $P = 0.0018$), 2-FLU (7.93 vs. 6.32; $P < 0.0001$), and 1-NAP (0.118 vs. 0.087; $P < 0.0001$). In the RCT, normal/fast nicotine metabolizers versus slow nicotine metabolizers had higher values of CEMA (0.76 vs. 0.64 nmol/mg; $P = 0.0074$) and PheT (2.79 vs. 2.44; $P = 0.0379$).

Results of the adjusted analyses examining biomarkers of effect by NMR group are displayed in **Fig. 3**. The inflammatory biomarker ICAM-1 measured in PATH was higher in normal/fast than slow nicotine metabolizers (314.76 vs. 290.73 ng/mL; $P = 0.0015$). The inflammatory biomarker PGEM measured in the RCT was higher in normal/fast than slow nicotine metabolizers (49.03 vs. 42.39 pmol/mg; $P = 0.0459$). The inflammatory biomarkers, IL6, hsCRP, and WBC, did not differ across NMR group. The oxidative stress biomarker PGF2α did not differ across NMR group (PATH: 1.85 vs. 1.68 pmol/mg; $P = 0.1075$; RCT: 1.21 vs. 1.15 pmol/mg; 0.2683).

Results of modeling NMR (log-transformed) as a continuous variable are displayed in Supplementary Tables S3 and S4. In adjusted analyses with the PATH Study, NMR was associated with increased levels of TNE ($P \leq 0.0001$), total NNAL ($P = 0.0017$), HMPMA ($P = 0.0079$), CEMA ($P = 0.0205$), PGA ($P = 0.0004$), MADA ($P = 0.0002$), 2-FLU ($P = 0.0041$), and 1-NAP ($P < 0.0001$). In the PATH Study, NMR was associated with decreased levels of total NNN ($P = 0.0028$). In the RCT, increased levels of NMR was associated with increased levels of 3-HPMA ($P = 0.0392$), CEMA ($P = 0.0001$), and PheT ($P = 0.0248$). In both datasets, continuous NMR was not associated with any of the biomarkers of effect.

Discussion

This study examined the association between NMR and intensity of smoking, nicotine dependence, biomarkers of TSNAs, VOCs, and PAHs, as well as the association between NMR and biomarkers of biological effect in two cross-sectional samples of non-Hispanic, white smokers. The results support the hypothesis that normal/fast nicotine metabolizers are heavier smokers, evidenced by an increase in levels of TNE by approximately 25 percent, and have higher levels of exposure to numerous carcinogens and toxicants found in tobacco and tobacco smoke when compared with slow metabolizers. A novel finding of the study was the observation that normal/fast nicotine metabolizers had higher levels of inflammation, measured by ICAM-1 and PGEM, than slow metabolizers. This study provides the first documentation that NMR is not only associated with smoking exposure but also biomarkers of biological effects that are integral in the development of tobacco-related disease.

Biomarkers of inflammation and oxidative stress have been observed to be affected by smoking (36, 37). ICAM-1 and PGEM were higher among normal/fast nicotine metabolizers. ICAM-1 has signaling properties in numerous cell types and is expressed in inflammatory conditions and chronic diseases including cancer and cardiovascular disease (38, 39). PGEM is a metabolite of the inflammatory mediator Prostaglandin E2 (PGE2; refs. 40, 41), which has been shown to promote tumor formation, growth, and metastasis and is the most abundant prostaglandin found in various types of malignancies including cancers of the lung, head, and neck (40). Higher levels of these inflammatory biomarkers among normal/fast metabolizers suggest greater disease risk and progression than slow metabolizers. Why ICAM-1 and PGEM were the only biomarkers of effect found to be

significantly elevated among normal/fast metabolizers may be due to their sensitivity to changes in smoking behavior. In a prior trial, levels of PGEM were found to decrease by 44% after smokers stopped smoking for 12 weeks, whereas levels of 8-iso-PGF_{2α} decreased by only 27% (42). The higher levels of inflammation in normal/fast metabolizers is consistent with prior studies that have shown levels of these biomarkers increase with pack-years and are correlated with cotinine levels (43–45). In a prior analysis of a Chinese cohort, NMR was significantly associated with lung cancer risk but not after adjustment for TNE (46). Indeed after adjustment for TNE, there was no difference between ICAM-1 and PGEM across NMR group in this study, suggesting that these relationships are driven by smoking intensity.

Unlike total NNAL and several other exposure biomarkers, total NNN was inversely correlated with NMR. A prior study among Alaska Natives also observed higher levels of total NNN in slow versus normal/fast nicotine metabolizers (47). The authors speculated that CYP2A6 may influence NNN metabolism and higher levels of NNN in slow metabolizers reflect lower bioactivation and therefore greater detoxification of NNN (47). However, another explanation is that this finding may reflect an artefact in the data as NNN measurements are highly prone to artefact formation during analysis (48, 49). Furthermore, only approximately 1% of the NNN dose is excreted in the urine and thus 99% of the NNN dose is not captured by the biomarker (48). This is in contrast to total NNAL, which is estimated to capture approximately 50% of the NNN dose (50).

Greater nicotine dependence has been examined as a potential explanation for why normal/fast nicotine metabolizers smoke more heavily than slow metabolizers (9, 27, 51–53). NMR was significantly associated with the HSI, but the relationship was primarily driven by CPD (and thus smoking intensity). There was no evidence for an association between NMR and the WISDM primary dependence motives subscale. Thus, the results of this study are consistent with the majority of prior studies that observed no association between NMR and various dependence scales (9, 27, 51–53).

While NMR modeled as the lowest quartile (slow metabolizers) versus the top three quartiles (normal/fast metabolizers) was associated with biomarkers of inflammation, NMR modeled as a continuous measure was not. In line with our results are prior studies that observed a threshold effect whereby mean plasma nicotine levels and quit rates were highest in the lowest quartile of NMR and then flattened out over the second, third, and fourth quartiles of NMR (27); thus the relationships were not linear. A limitation of prior studies is that the distribution of NMR was defined within each sample and this has resulted in varying NMR cutoff points to distinguish slow versus normal/fast nicotine metabolizers (26–31). A strength of this study was the use of a U.S. representative study of smokers to determine the NMR cutoff point (0.26 based on the molar ratio of free 3-hydroxycotinine to free cotinine in serum). Given the significant relationships observed in this study, the NMR cutoff point of 0.26 could serve as a measure for identifying non-Hispanic, white smokers who are potentially at the greatest risk for tobacco-related disease.

Another strength of the study was the use of data from two separate studies that allowed for a comprehensive array of biomarkers for study. The PATH Study and the RCT varied in inclusion/exclusion criteria and methods of recruitment, which likely resulted in the observed differences in the distribution of NMR across the two studies, as well as differences in participant characteristics. In addition, biomarkers were analyzed by different labs with different analytic approaches. For

example, in the PATH study TNE was measured as a composite of seven metabolites (TNE7) while in the RCT TNE was a composite of three metabolites (TNE3). The ratio of TNE7 to TNE3 averages 1.18 (54). Thus, these two measures for TNE are correlated but have different means (as shown in the data with PATH participants' having a greater mean value for TNE). Despite these differences, levels of biomarkers and their patterns across NMR strata were similar across the two studies and demonstrate consistency of the results.

There are limitations to the current study. Variation in nicotine metabolism pathways, other than those catalyzed by CYP2A6 such as UGT2B10, can affect the accuracy of the NMR as measured in this study (free 3HCOT/free COT) as a measure of CYP2A6 activity (12, 55). Compared to 1% of whites, approximately 15% of African American smokers do not glucuronidate cotinine due to the presence of the *UGT2B10* splice variant (12, 55). As a result, some African Americans could be misclassified as having a lower NMR when *UGT2B10* is not also taken into account (12, 55). *UGT2B10* genotype or its phenotype, ratio of total COT to free COT, was not available in the PATH data. Thus, this study was restricted to participants of non-Hispanic white race/ethnicity and findings may not be generalizable to other racial/ethnic groups. Another limitation is that the results are not generalizable to non-daily or light smokers, where NMR is less predictive of smoking behavior (56, 57), and the use of a urinary COT level of >1,000 ng/mL for inclusion may have hindered the generalizability of the results to some moderate smokers. In the clinical trial sample, several biomarkers of exposure were higher among normal/fast versus slow metabolizers, but the differences were not statistically significant. Given that several of these biomarkers reached significance in the PATH study, the lack of significance in the clinical trial sample could be due to the fewer number of slow metabolizers ($n = 148$ vs. $n = 343$). Finally, indicators of inflammation and oxidative stress and the metabolites studied, with the exception of total NNAL and NNN, are not specific to tobacco use and therefore may reflect environmental and/or endogenous exposures (23, 58).

In conclusion, the results are suggestive that normal/fast nicotine metabolizers of non-Hispanic white race may be at increased risk for tobacco-related disease due to greater smoking intensity, higher exposure to numerous toxicants and carcinogens, and higher levels of inflammation when compared with slow nicotine metabolizers of non-Hispanic white race. Results provide support for the NMR as a biomarker for understanding a smoker's exposure and potential risk for tobacco-related disease.

Disclosure of Potential Conflicts of Interest

N.L. Benowitz is a consultant for Pfizer and Achieve Life Sciences and has provided expert testimony against tobacco companies. M. Kotlyar reports receiving a Global Research Award for Nicotine Dependence (GRAND) program funded by Pfizer. No potential conflicts of interest were disclosed by the other authors.

Disclaimer

The contents and views in this manuscript are those of the authors and should not be construed to represent the views of the NIH or any of the sponsoring organizations and agencies of the U.S. government.

Authors' Contributions

Conception and design: D.M. Carroll, S.E. Murphy, N.L. Benowitz, S.S. Hecht, E.C. Donny

Development of methodology: D.M. Carroll, S.E. Murphy, D.K. Hatsukami

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): D.M. Carroll, S.E. Murphy, N.L. Benowitz, S.G. Carmella, R.G. Vandrey, E.C. Donny, D.K. Hatsukami

Carroll et al.

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): D.M. Carroll, N.L. Benowitz, A.A. Strasser, F.J. McClernon, S.S. Dermody, E.C. Donny, D.K. Hatsukami

Writing, review, and/or revision of the manuscript: D.M. Carroll, S.E. Murphy, N.L. Benowitz, A.A. Strasser, M. Kotlyar, S.S. Hecht, F.J. McClernon, L.R. Pacek, S.S. Dermody, R.G. Vandrey, E.C. Donny, D.K. Hatsukami

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): F.J. McClernon

Study supervision: F.J. McClernon

Acknowledgments

Research reported in this publication was supported by National Institute on Drug Abuse of the NIH under award number U54 DA031659 (to D.K. Hatsukami

and E.C. Donny) and under award number K01DA043413 (to L.R. Pacek). Research reported in this publication was supported by NIH, National Research Service Award T32 DA007097 (to D.M. Carroll). Mass spectrometry for the RCT was conducted in the Analytical Biochemistry Shared Resource of the Masonic Cancer Center, supported in part by National Cancer Institute Cancer Center Support grant P30CA07759.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received June 5, 2019; revised August 23, 2019; accepted January 24, 2020; published first February 12, 2020.

References

- Benowitz NL. Nicotine addiction. *N Engl J Med* 2010;362:2295–303.
- Benowitz NL, Hukkanen J, Jacob P III. Nicotine chemistry, metabolism, kinetics and biomarkers. *Handb Exp Pharmacol* 2009;29–60.
- Xu C, Goodz S, Sellers EM, Tyndale RF. CYP2A6 genetic variation and potential consequences. *Adv Drug Deliv Rev* 2002;54:1245–56.
- Dempsey DN. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. *Clin Pharmacol Ther* 2004;76:64–72.
- Park SL, Tiirikainen MI, Patel YM, Wilkens LR, Stram DO, Le Marchand L, et al. Genetic determinants of CYP2A6 activity across racial/ethnic groups with different risks of lung cancer and effect on their smoking intensity. *Carcinogenesis* 2016;37:269–79.
- Malaiyandi V, Goodz SD, Sellers EM, Tyndale RF. CYP2A6 genotype, phenotype, and the use of nicotine metabolites as biomarkers during ad libitum smoking. *Cancer Epidemiol Biomarkers Prev* 2006;15:1812–19.
- Swan GE, Lessov-Schlaggar CN, Bergen AW, He Y, Tyndale RF, Benowitz NL. Genetic and environmental influences on the ratio of 3-hydroxycotinine to cotinine in plasma and urine. *Pharmacogenet Genomics* 2009;19:388–98.
- West O, Hajek P, McRobbie H. Systematic review of the relationship between the 3-hydroxycotinine/cotinine ratio and cigarette dependence. *Psychopharmacology (Berl)* 2011;218:313–22.
- Strasser AA, Benowitz NL, Pinto AG, Tang KZ, Hecht SS, Carmella SG, et al. Nicotine metabolite ratio predicts smoking topography and carcinogen biomarker level. *Cancer Epidemiol Biomarkers Prev* 2011;20:234–8.
- Mercincavage M, Lochbuehler K, Wileyto EP, Benowitz NL, Tyndale RF, Lerman C, et al. Association of reduced nicotine content cigarettes with smoking behaviors and biomarkers of exposure among slow and fast nicotine metabolizers: A nonrandomized clinical trial. *JAMA Netw Open* 2018;1:e181346.
- Hyland A, Ambrose BK, Conway KP, Borek N, Lambert E, Carusi C, et al. Design and methods of the population assessment of tobacco and health (PATH) Study. *Tob Control* 2017;26:371–8.
- Murphy SE. Nicotine metabolism and smoking: ethnic differences in the role of P450 2A6. *Chem Res Toxicol* 2017;30:410–9.
- Hatsukami DK, Luo X, Jensen JA, al?Absi M, Allen SS, Carmella SG, et al. Effect of immediate vs gradual reduction in nicotine content of cigarettes on biomarkers of smoke exposure: A randomized clinical trial. *JAMA* 2018;320:880–91.
- United States Department of Health and Human Services, National Institutes of Health, National Institute on Drug, U.S. Food and Drug Administration, Center for Tobacco Products. Population assessment of tobacco and health (PATH) study [United States] biomarker restricted-use files. Inter-university Consortium for Political and Social Research [distributor]; 2019. Available from: <https://www.icpsr.umich.edu/icpsrweb/NAHDAP/studies/36840>.
- Heatherton TF, Kozlowski LT, Frecker RC, Rickert W, Robinson J. Measuring the heaviness of smoking: using self-reported time to the first cigarette of the day and number of cigarettes smoked per day. *Addiction* 1989;84:791–9.
- Smith SS, Piper ME, Bolt DM, Fiore MC, Wetter DW, Cinciripini PM, et al. Development of the brief Wisconsin inventory of smoking dependence motives. *Nicotine Tob Res* 2010;12:489–99.
- Strong DR, Pearson J, Ehler S, Kirchner T, Abrams D, Taylor K, et al. Indicators of dependence for different types of tobacco product users: descriptive findings from wave 1 (2013–2014) of the population assessment of tobacco and health (PATH) study. *Drug Alcohol Depend* 2017;178:257–66.
- Murphy S, Villalta P, Ho S, Vonweymarn L. Analysis of [3',3'-d(2)]-nicotine and [3',3'-d(2)]-cotinine by capillary liquid chromatography-electrospray tandem mass spectrometry. *J Chromatogr B* 2007;857:1–8.
- Carmella SG, Ming X, Olvera N, Brookmeyer C, Yoder A, Hecht SS. High throughput liquid and gas chromatography-tandem mass spectrometry assays for tobacco-specific nitrosamine and polycyclic aromatic hydrocarbon metabolites associated with lung cancer in smokers. *Chem Res Toxicol* 2013;26:1209–17.
- Carmella SG, Chen M, Zarth A, Hecht SS. High throughput liquid chromatography-tandem mass spectrometry assay for mercapturic acids of acrolein and crotonaldehyde in cigarette smokers' urine. *J Chromatogr B* 2013;935:36–40.
- Zarth AT, Carmella SG, Le CT, Hecht SS. Effect of cigarette smoking on urinary 2-hydroxypropylmercapturic acid, a metabolite of propylene oxide. *J Chromatogr B* 2014;953–954:126–31.
- Carmella SG, Chen M, Han S, Briggs A, Jensen J, Hatsukami DK, et al. Effects of smoking cessation on eight urinary tobacco carcinogen and toxicant biomarkers. *Chem Res Toxicol* 2009;22:734–41.
- Chen M, Carmella SG, Sipe C, Jensen J, Luo X, Le CT, et al. Longitudinal stability in cigarette smokers of urinary biomarkers of exposure to the toxicants acrylonitrile and acrolein. *PLoS One* 2019;14:e0210104.
- Yan W, Byrd GD, Ogden MW. Quantitation of isoprostane isomers in human urine from smokers and nonsmokers by LC-MS/MS. *J Lipid Res* 2007;48:1607–17.
- Neale JR, Dean BJ. Liquid chromatography-tandem mass spectrometric quantification of the dehydration product of tetranor PGE-M, the major urinary metabolite of prostaglandin E(2) in human urine. *J Chromatogr B* 2008;871:72–7.
- Lerman C, Tyndale R, Patterson F, Wileyto E, Shields P, Pinto A, et al. Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. *Clin Pharmacol Ther* 2006;79:600–8.
- Schnoll RA, Patterson F, Wileyto EP, Tyndale RF, Benowitz N, Lerman C. Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study. *Pharmacol Biochem Behav* 2009;92:6–11.
- Lerman C, Jepson C, Wileyto EP, Patterson F, Schnoll R, Mroziewicz M, et al. Genetic variation in nicotine metabolism predicts the efficacy of extended-duration transdermal nicotine therapy. *Clin Pharmacol Ther* 2010;87:553–7.
- Patterson F, Schnoll R, Wileyto E, Pinto A, Epstein L, Shields P, et al. Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion. *Clin Pharmacol Ther* 2008;84:320–5.
- Schnoll RA, Wileyto EP, Leone FT, Tyndale RF, Benowitz NL. High dose transdermal nicotine for fast metabolizers of nicotine: a proof of concept placebo-controlled trial. *Nicotine Tob Res* 2013;15:348–54.
- Lerman C, Schnoll RA, Hawk LW, Cinciripini P, George TP, Wileyto EP, et al. Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. *Lancet Respir Med* 2015;3:131–8.
- Benowitz N, Lessovschlaggar C, Swan G, JACOBI P 3rd. Female sex and oral contraceptive use accelerate nicotine metabolism. *Clin Pharmacol Ther* 2006;79:480–8.
- Allenby CE, Boylan KA, Lerman C, Falcone M. Precision medicine for tobacco dependence: development and validation of the nicotine metabolite ratio. *J Neuroimmune Pharmacol* 2016;11:471–83.
- McCarthy PJ. Pseudoreplication: further evaluation and applications of the balanced half-sample technique. *Vital Health Stat* 2 1969:1–24.

35. Judkins DR. Fay's method for variance estimation. *J Off Stat* 1990;6:223–39.
36. United States Department of Health and Human Services. How tobacco smoke causes disease: the biology and behavioral basis for smoking-attributable disease: a report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. 2010;2. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK53017/>.
37. Chang CM, Cheng Y-C, Cho TM, Mishina EV, Del Valle-Pinero AY, van Bommel DM, et al. Biomarkers of potential harm: summary of an FDA-sponsored public workshop. *Nicotine Tob Res* 2019;21:3–13.
38. Frank PG, Lisanti MP. ICAM-1: role in inflammation and in the regulation of vascular permeability. *Am J Physiol Heart Circ Physiol* 2008;295:H926–H927.
39. Lawson C, Wolf S. ICAM-1 signaling in endothelial cells. *Pharmacol Rep* 2009;61:22–32.
40. Wang D, DuBois RN. Urinary PGE-M: a promising cancer biomarker. *Cancer Prev Res* 2013;6:507–10.
41. Seyberth HW, Sweetman BJ, Frolich JC, Oates JA. Quantifications of the major urinary metabolite of the E prostaglandins by mass spectrometry: evaluation of the method's application to clinical studies. *Prostaglandins* 1976;11:381–97.
42. McElroy JP, Carmella SG, Heskin AK, Tang MK, Murphy SE, Reisinger SA, et al. Effects of cessation of cigarette smoking on eicosanoid biomarkers of inflammation and oxidative damage. *PLoS One* 2019.
43. Gross ND. Levels of prostaglandin E metabolite, the major urinary metabolite of prostaglandin E2, are increased in smokers. *Clin Cancer Res* 2005;11:6087–93.
44. Levitzky YS, Guo C-Y, Rong J, Larson MG, Walter RE, Keaney JF, et al. Relation of smoking status to a panel of inflammatory markers: the framingham offspring. *Atherosclerosis* 2008;201:217–24.
45. Palmer RM, Scott DA, Meekin TN, Poston RN, Odell EW, Wilson RF. Potential mechanisms of susceptibility to periodontitis in tobacco smokers. *J Periodontol Res* 1999;34:363–9.
46. Yuan J-M, Nelson HH, Butler LM, Carmella SG, Wang R, Kuriger-Laber JK, et al. Genetic determinants of cytochrome P450 2A6 activity and biomarkers of tobacco smoke exposure in relation to risk of lung cancer development in the Shanghai cohort study. *Int J Cancer* 2016;138:2161–71.
47. Zhu AZX, Binnington MJ, Renner CC, Lanier AP, Hatsukami DK, Stepanov I, et al. Alaska native smokers and smokeless tobacco users with slower CYP2A6 activity have lower tobacco consumption, lower tobacco-specific nitrosamine exposure and lower tobacco-specific nitrosamine bioactivation. *Carcinogenesis* 2013;34:93–101.
48. Urban M, Scherer G, Kavvadias D, Hagedorn H-W, Feng S, Serafin R, et al. Quantitation of N'-nitrososornicotine (NNN) in smokers' urine by liquid chromatography-tandem mass spectrometry. *J Anal Toxicol* 2009;33:260–5.
49. Kotandeniya D, Carmella SG, Pillsbury ME, Hecht SS. Combined analysis of N'-Nitrososornicotine and 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol in the urine of cigarette smokers and e-cigarette users. *J Chromatogr B* 2015;1007:121–6.
50. Hecht SS. Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. *Chem Res Toxicol* 1998;11:559–603.
51. Schnoll RA, George TP, Hawk L, Cinciripini P, Wileyto P, Tyndale RF. The relationship between the nicotine metabolite ratio and three self-report measures of nicotine dependence across sex and race. *Psychopharmacology* 2014;231:2515–23.
52. Pomerleau C, Benowitz N, Jacob P, Pomerleau O. Nicotine metabolite ratio as a predictor of cigarette consumption. *Nicotine Tob Res* 2003;5:621–24.
53. Kandel DB, Hu M-C, Schaffran C, Udry JR, Benowitz NL. Urine nicotine metabolites and smoking behavior in a multiracial/multiethnic national sample of young adults. *Am J Epidemiol* 2007;165:901–10.
54. Benowitz NL, St. Helen G, Nardone N, Cox LS, Jacob P. Urine metabolites for estimating daily intake of nicotine from cigarette smoking. *Nicotine Tob Res* 2019.
55. Murphy SE, Park S-SL, Thompson EF, Wilkens LR, Patel Y, Stram DO, et al. Nicotine N-glucuronidation relative to N-oxidation and C-oxidation and UGT2B10 genotype in five ethnic/racial groups. *Carcinogenesis* 2014;35:2526–33.
56. Ho M, Mwenifumbo J, Al Koudsi N, Okuyemi K, Ahluwalia J, Benowitz N, et al. Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. *Clin Pharmacol Ther* 2009;85:635–43.
57. Carroll DM, Wagener TL, Stephens LD, Brame LS, Thompson DM, Beebe LA. The relationship between nicotine metabolism and nicotine and carcinogen exposure among American Indian commercial cigarette smokers and electronic nicotine delivery system users. *Addict Behav* 2019;92:58–63.
58. Carmella SG, Heskin AK, Tang MK, Jensen J, Luo X, Le CT, et al. Longitudinal stability in cigarette smokers of urinary eicosanoid biomarkers of oxidative damage and inflammation. *PLoS One* 2019;14:e0215853.

Cancer Epidemiology, Biomarkers & Prevention

Relationships between the Nicotine Metabolite Ratio and a Panel of Exposure and Effect Biomarkers: Findings from Two Studies of U.S. Commercial Cigarette Smokers

Dana M. Carroll, Sharon E. Murphy, Neal L. Benowitz, et al.

Cancer Epidemiol Biomarkers Prev 2020;29:871-879. Published OnlineFirst February 12, 2020.

Updated version Access the most recent version of this article at:
doi:[10.1158/1055-9965.EPI-19-0644](https://doi.org/10.1158/1055-9965.EPI-19-0644)

Supplementary Material Access the most recent supplemental material at:
<http://cebp.aacrjournals.org/content/suppl/2020/02/12/1055-9965.EPI-19-0644.DC1>

Cited articles This article cites 52 articles, 6 of which you can access for free at:
<http://cebp.aacrjournals.org/content/29/4/871.full#ref-list-1>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://cebp.aacrjournals.org/content/29/4/871>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.